Terms: = Brain cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
1593 results:
1. cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.
Goyette MA; Stevens LE; DePinho CR; Seehawer M; Nishida J; Li Z; Wilde CM; Li R; Qiu X; Pyke AL; Zhao S; Lim K; Tender GS; Northey JJ; Riley NM; Long HW; Bertozzi CR; Weaver VM; Polyak K
Proc Natl Acad Sci U S A; 2024 May; 121(20):e2322688121. PubMed ID: 38709925
[TBL] [Abstract] [Full Text] [Related]
2. Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines.
Stouffer M; Wandling E; Dickson L; Lin S; Duan H; Powe E; Jean-Louis D; Tiwari AK; Amos S
Cancer Rep (Hoboken); 2024 May; 7(5):e2051. PubMed ID: 38702989
[TBL] [Abstract] [Full Text] [Related]
3. Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with egfr-Mutant Non-Small Cell Lung cancer.
Tozuka T; Noro R; Mizutani H; Kurimoto F; Hakozaki T; Hisakane K; Naito T; Takahashi S; Taniuchi N; Yajima C; Hosomi Y; Hirose T; Minegishi Y; Okano T; Kamio K; Yamaguchi T; Seike M;
Lung Cancer; 2024 May; 191():107540. PubMed ID: 38614069
[TBL] [Abstract] [Full Text] [Related]
4. Mobocertinib in Patients with egfr Exon 20 Insertion-Positive Non-Small Cell Lung cancer (MOON): An International Real-World Safety and Efficacy Analysis.
Illini O; Saalfeld FC; Christopoulos P; Duruisseaux M; Vikström A; Peled N; Demedts I; Dudnik E; Eisert A; Hashemi SMS; Janzic U; Kian W; Mohorcic K; Mohammed S; Silvoniemi M; Rothschild SI; Schulz C; Wesseler C; Addeo A; Armster K; Itchins M; Ivanović M; Kauffmann-Guerrero D; Koivunen J; Kuon J; Pavlakis N; Piet B; Sebastian M; Velthaus-Rusik JL; Wannesson L; Wiesweg M; Wurm R; Albers-Leischner C; Aust DE; Janning M; Fabikan H; Herold S; Klimova A; Loges S; Sharapova Y; Schütz M; Weinlinger C; Valipour A; Overbeck TR; Griesinger F; Jakopovic M; Hochmair MJ; Wermke M
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612799
[TBL] [Abstract] [Full Text] [Related]
5. The application of different machine learning models based on PET/CT images and egfr in predicting brain metastasis of adenocarcinoma of the lung.
Kong C; Yin X; Zou J; Ma C; Liu K
BMC Cancer; 2024 Apr; 24(1):454. PubMed ID: 38605303
[TBL] [Abstract] [Full Text] [Related]
6. Clinical status and perspective on the application of immunotherapy combined with chemotherapy in advanced non-small cell lung cancer: a review.
Wang T; Zhang L; Cheng Y
Chin Clin Oncol; 2024 Apr; 13(2):26. PubMed ID: 38600808
[TBL] [Abstract] [Full Text] [Related]
7. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Chen MF; Song Z; Yu HA; Sequist LV; Lovly CM; Mitchell EP; Moscow JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Umemura Y; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2024 Apr; 8():e2300454. PubMed ID: 38591867
[TBL] [Abstract] [Full Text] [Related]
8. Exploring ncRNA-mediated regulation of egfr signalling in glioblastoma: From mechanisms to therapeutics.
Thapa R; Afzal M; Goyal A; Gupta G; Bhat AA; Almalki WH; Kazmi I; Alzarea SI; Shahwan M; Kukreti N; Ali H; Dureja H; Kumar P; Singh TG; Kuppusamy G; Singh SK; Dua K
Life Sci; 2024 May; 345():122613. PubMed ID: 38582393
[TBL] [Abstract] [Full Text] [Related]
9. Harnessing the potential of nanoengineered siRNAs carriers for target responsive glioma therapy: Recent progress and future opportunities.
Ahirwar K; Kumar A; Srivastava N; Saraf SA; Shukla R
Int J Biol Macromol; 2024 May; 266(Pt 1):131048. PubMed ID: 38522697
[TBL] [Abstract] [Full Text] [Related]
10. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation egfr-TKI in egfr-mutated lung adenocarcinoma with brain metastases.
Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
[TBL] [Abstract] [Full Text] [Related]
11. N6-isopentenyladenosine inhibits aerobic glycolysis in glioblastoma cells by targeting PKM2 expression and activity.
Pagano C; Coppola L; Navarra G; Avilia G; Savarese B; Torelli G; Bruzzaniti S; Piemonte E; Galgani M; Laezza C; Bifulco M
FEBS Open Bio; 2024 May; 14(5):843-854. PubMed ID: 38514913
[TBL] [Abstract] [Full Text] [Related]
12. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring egfr20 R776S, C797S, and egfr21 L858R compound egfr mutations: a case report.
Jia G; Bashir S; Ye M; Li Y; Lai M; Cai L; Xu M
Anticancer Drugs; 2024 Jul; 35(6):542-547. PubMed ID: 38513197
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Management of Patients with Non-Small Cell Lung cancer, brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review.
Khasraw M; Yalamanchili P; Santhanagopal A; Wu C; Salas M; Meng J; Karnoub M; Esker S; Felip E
Adv Ther; 2024 May; 41(5):1815-1842. PubMed ID: 38509433
[TBL] [Abstract] [Full Text] [Related]
14. Targeted dual degradation of HER2 and egfr obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract] [Full Text] [Related]
15. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract] [Full Text] [Related]
16. Real-World treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic impact of clinical and radiological factors on leptomeningeal metastasis from solid cancers.
Nakagawa K; Takano K; Nishino K; Ohe S; Nakayama T; Arita H
J Neurooncol; 2024 May; 167(3):397-406. PubMed ID: 38430420
[TBL] [Abstract] [Full Text] [Related]
18. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S; Salib S; Balasubramaniam M; Aboud O
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
[TBL] [Abstract] [Full Text] [Related]
19. Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.
Repici A; Ardizzone A; De Luca F; Colarossi L; Prestifilippo A; Pizzino G; Paterniti I; Esposito E; Capra AP
Cells; 2024 Feb; 13(4):. PubMed ID: 38391974
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from egfr+ NSCLC: an expanded, single-arm, phase II clinical trial.
Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
[TBL] [Abstract] [Full Text] [Related]
[Next]